The Quantellect read.As of Nov 19, 2026, 6 active firms cover Aligos Therapeutics Inc: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $20.00 to $50.00 (about 2.5x), a sign of real disagreement on valuation. The average target of $38.50 sits 2956% above the current $1.26. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 892% this year and -77% next, consensus EPS building from about $-1.52 next quarter toward $-5.78 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$38.50
+2955.6% upside
Average target across 6 active firms as of Nov 19, 2026 vs $1.26 current
Highest Target$50.00
Average Target$38.50
Lowest Target$20.00
Detailed analyst forecasts for ALGS
Showing 1–5 of 5 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 6 of 6 active firms rate ALGS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ALGS EPS & revenue forecast
EPS · NEXT QUARTER
$-1.52
Range $-1.77 – $-1.31 · 4 analysts · -31% YoY
Next period, 4 analysts expect Aligos Therapeutics Inc to earn $-1.52 a share (range $-1.77 – $-1.31), versus $-2.21 a year earlier. Full-year consensus is $-6.36, growing to $-5.78 the year after.
REVENUE · NEXT QUARTER
$220.0K
Range $0 – $1.0M · 4 analysts · +8% YoY
Revenue is expected to reach $220.0K (range $0 – $1.0M), +8.0% year-over-year. Full-year consensus is $33.7M, rising to $6.2M next year.
Top analysts covering Aligos Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ALGS.
#1
Ed Arce
HC Wainwright & Co. · Rank #168
Buy
$70.00+5455.6% to target
Overall win rate
44%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$50.00+3868.3% to target
Overall win rate
36%
+ Follow
#3
AL
Anthea Li
Jefferies
Buy
$48.00+3709.5% to target
Coverage
—
+ Follow
#4
Michael Yee
UBS
Buy
$20.00+1487.3% to target
Coverage
—
+ Follow
#5
DB
Daniel Brims
Lake Street
Buy
$45.00+3471.4% to target
Coverage
—
+ Follow
ALGS stock forecast FAQ
What is ALGS's average 12-month price target?+
The 6 active firms with a live target average $38.50 for Aligos Therapeutics Inc over the next 12 months, ranging from a $50.00 high to a $20.00 low, as of Nov 19, 2026.
Is ALGS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ALGS?+
The Street-high target is $50.00 (HC Wainwright & Co.), and the Street-low is $20.00 (Cantor Fitzgerald). The average of all 6 active-firm targets is $38.50.
How many active Wall Street firms cover ALGS?+
6 active firms have a recognized rating on Aligos Therapeutics Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ALGS?+
Among analysts who currently cover ALGS, Ed Arce of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #168). Their current call is Buy with a $70.00 target.
What is Aligos Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.52 per share (range $-1.77 – $-1.31) across 4 analysts. Full-year EPS is projected at $-6.36, rising to $-5.78 the following year.
How much revenue is Aligos Therapeutics Inc expected to report next quarter?+
Consensus revenue is $220.0K (range $0 – $1.0M). Full-year revenue is projected at $33.7M, growing to $6.2M next year.
Have analysts been upgrading or downgrading ALGS lately?+
As of Nov 19, 2026, 6 of 6 active firms rate ALGS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ALGS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.